Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

Full text
Author(s):
Forlenza, Orestes V. [1, 2] ; Diniz, Breno S. ; Radanovic, Marcia ; Santos, Franklin S. ; Talib, Leda L. ; Gattaz, Wagner F.
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Fac Med, Lab Neurosci LIM 27, Inst Psychiat, BR-05403010 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Lab Neurosci LIM 27, Dept Psychiat, BR-05403010 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: BRITISH JOURNAL OF PSYCHIATRY; v. 198, n. 5, p. 351-356, MAY 2011.
Web of Science Citations: 187
Abstract

Background Two recent clinical studies support the feasibility of trials to evaluate the disease-modifying properties of lithium in Alzheimer's disease, although no benefits were obtained from short-term treatment. Aims To evaluate the effect of long-term lithium treatment on cognitive and biological outcomes in people with amnestic mild cognitive impairment (aMCI). Method Forty-five participants with aMCI were randomised to receive lithium (0.25-0.5mmol/l) (n=24) or placebo (n = 21) in a 12-month, double-blind trial. Primary outcome measures were the modification of cognitive and functional test scores, and concentrations of cerebrospinal fluid (CSF) biomarkers (amyloid-beta peptide (A beta(42)), total tau (T-tau), phosphorylated-tau) (P-tau). Trial registration: NCT01055392. Results Lithium treatment was associated with a significant decrease in CSF concentrations of P-tau (P=0.03) and better perform-ance on the cognitive subscale of the Alzheimer's Disease Assessment Scale and in attention tasks. Overall tolerability of lithium was good and the adherence rate was 91%. Conclusions The present data support the notion that lithium has disease-modifying properties with potential clinical implications in the prevention of Alzheimer's disease. (AU)

FAPESP's process: 02/13633-7 - Phospholipid metabolism in neuropsychiatric disorders
Grantee:Wagner Farid Gattaz
Support Opportunities: Research Projects - Thematic Grants